Stock A065170 BL PHARMTECH CORP.
Add to a list
To use this feature you must be a member
Log inSign up

News BL Pharmtech Corp.

Equities

A065170

KR7065170003

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
485 KRW -1.62% Intraday chart for BL Pharmtech Corp. +3.19% -3.96%
Mar. 28 Youngchul Park completed the acquisition of 24.43% stake in BL Pharmtech Corp. (KOSDAQ : A065170) from Bioleaders Corporation. CI
Mar. 20 BL Pharmtech Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Youngchul Park completed the acquisition of 24.43% stake in BL Pharmtech Corp. (KOSDAQ : A065170) from Bioleaders Corporation.
CI
BL Pharmtech Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Youngchul Park agreed to acquire 24.43% stake in BL Pharmtech Corp. (KOSDAQ : A065170) from Bioleaders Corporation for KRW 9.3 billion.
CI
BL Pharmtech agreed to acquire an additional 30.89% stake in Anyone F&C Co., Ltd. for KRW 9 billion
CI
Kwang Dong Pharmaceutical Co., Ltd. agreed to acquire a 58.73% stake in BL Healthcare Corp. from BL Healthcare Corp. for KRW 30 billion
CI
BL Pharmtech Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
BL Pharmtech Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
BL Pharmtech Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Next Bt Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Next Bt Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Next Bt Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Next Bt Co., Ltd. announced that it has received KRW 6 billion in funding from Bioleaders Corporation, Dk Life Science Co., Ltd. and other investors
CI
Next Bt Co., Ltd. announced that it expects to receive KRW 6 billion in funding from Bioleaders Corporation, Dk Life Science Co., Ltd. and other investors
CI
Next Bt Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
Next Bt Co., Ltd. announced that it has received KRW 10.4 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Mirae Asset Venture Investment Co., Ltd., Mirae Asset Securities Co., Ltd.
CI
Next Bt Co., Ltd. announced that it expects to receive KRW 10.4 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Mirae Asset Venture Investment Co., Ltd., Mirae Asset Securities Co., Ltd.
CI
Next Bt Co., Ltd. completed the acquisition of the remaining 77.7% stake in TCM Biosciences Inc..
CI
Next Bt Co., Ltd. agreed to acquire the remaining 77.7% stake in TCM Biosciences Inc. for KRW 37 billion.
CI
Next Bt Co., Ltd. acquired 22.25% stake in TCM Biosciences Inc. from Park Young Chul for KRW 15.9 billion.
CI
Next Bt Co., Ltd. announced that it has received KRW 6.5 billion in funding
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A065170 Stock
  4. News BL Pharmtech Corp.